Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Nipent pentostatin: Marketed to treat hairy cell leukemia

In an investigator-led U.S. study, all 5 pediatric patients

Read the full 94 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE